Is cimepilimab an immune drug or a targeted drug? Which class of therapeutic drugs does it belong to?

Cemiplimab is an immunotherapy drug that belongs to the immune checkpoint inhibitor class. It works by acting on specific parts of the immune system to help the body recognize and attack cancer cells. Cimepilimab is mainly used to treat certain types of cancer, particularly non-small cell lung cancer and cutaneous squamous cell carcinoma.

The mechanism of action of cimepilimab is by inhibiting the interaction between the PD-1 (programmed death protein 1) receptor and its ligand PD-L1. PD-1 is an immune checkpoint molecule that usually plays an inhibitory role in immune responses. When PD-1 binds to PD-L1, it inhibits immune cell function, helping cancer cells evade immune system surveillance. By blocking this interaction, cimepilimab restores immune cell function and enhances the body's anti-cancer immune response.

Unlike targeted drugs, cimepilimab does not directly act on the cancer cells themselves, but indirectly treats cancer by activating and enhancing the patient's immune system. Targeted drugs usually act on specific molecules or pathways to directly affect the proliferation or growth of cancer cells, while immunotherapy drugs such as cimepilimab work by modulating the immune system to recognize and kill cancer cells.
Therefore, cimepilimab is an immunotherapy drug, not a targeted drug. It works by harnessing the potential of the immune system to enhance its ability to attack cancer, and is particularly useful for those types of cancer where traditional chemotherapy is less effective or cannot be controlled with targeted therapies. The immunotherapy method of cimipilimab provides new treatment options for cancer patients, especially important progress has been made in the field of immunotherapy.
Reference: https://www.libtayohcp.com/